(JREB) JPMorgan s Ireland ICAV - Ratings and Ratios
Corporate Bonds, European Bonds, Fixed Income
Description: JREB JPMorgan s Ireland ICAV
The JPMorgan ETFs Ireland ICAV - EUR Corporate Bond Research Enhanced Index ESG UCITS ETF EUR Acc EUR (SW:JREB) is an exchange-traded fund that tracks the Morningstar EZN Corp Bd GR EUR index, providing exposure to EUR-denominated corporate bonds. As a research-enhanced index ETF, it aims to outperform the benchmark through a rules-based investment approach.
With an AUM of approximately €5.987 billion, the fund has a significant presence in the market. The ETFs focus on ESG (Environmental, Social, and Governance) considerations aligns with the growing demand for sustainable investing. The funds investment strategy is designed to capture the returns of the EUR corporate bond market while minimizing the impact of credit risk.
From a technical analysis perspective, the ETFs price action indicates a stable trend, with the short-term moving averages (SMA20 and SMA50) above the long-term SMA200, suggesting a bullish outlook. The Average True Range (ATR) of 0.07 (0.07%) implies relatively low volatility, making it an attractive option for investors seeking stable returns. Key Performance Indicators (KPIs) such as the Sharpe Ratio, Information Ratio, and Tracking Error would provide further insights into the funds risk-adjusted performance and its ability to track the underlying index.
To evaluate the ETFs performance, we can consider additional KPIs such as Yield to Maturity, Duration, and Credit Quality. These metrics would help investors understand the funds exposure to interest rate risk, credit risk, and potential returns. Furthermore, analyzing the ETFs sector allocation, issuer diversification, and ESG ratings would provide a more comprehensive understanding of its investment profile and potential for long-term growth.
Additional Sources for JREB ETF
JREB ETF Overview
Market Cap in USD | 6,995m |
Category | EUR Corporate Bond |
IPO / Inception | 2018-12-05 |
JREB ETF Ratings
Growth Rating | 25.3 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | 9.52 |
Analysts | - |
Fair Price Momentum | 100.23 EUR |
Fair Price DCF | - |
JREB Dividends
Currently no dividends paidJREB Growth Ratios
Growth Correlation 3m | 91.9% |
Growth Correlation 12m | 96.4% |
Growth Correlation 5y | 67% |
CAGR 5y | 0.24% |
CAGR/Max DD 5y | 0.01 |
Sharpe Ratio 12m | -0.68 |
Alpha | 9.86 |
Beta | -0.042 |
Volatility | 1.38% |
Current Volume | 0k |
Average Volume 20d | 0k |
Stop Loss | 103.9 (-3%) |
As of July 16, 2025, the stock is trading at EUR 107.12 with a total of 0 shares traded.
Over the past week, the price has changed by -0.10%, over one month by +0.36%, over three months by +1.15% and over the past year by +5.29%.
Neither. Based on ValueRay´s Analyses, JPMorgan s Ireland ICAV is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 25.32 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JREB is around 100.23 EUR . This means that JREB is currently overvalued and has a potential downside of -6.43%.
JPMorgan s Ireland ICAV has no consensus analysts rating.
According to our own proprietary Forecast Model, JREB JPMorgan s Ireland ICAV will be worth about 108.3 in July 2026. The stock is currently trading at 107.12. This means that the stock has a potential upside of +1.05%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 108.3 | 1.1% |